UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000050025 |
|---|---|
| Receipt number | R000056991 |
| Scientific Title | Study on effects of banana intake and intake time on blood glucose levels and spike. |
| Date of disclosure of the study information | 2023/01/13 |
| Last modified on | 2023/07/14 09:10:24 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
Study on effects of banana intake and intake time on blood glucose levels and spike.
Acronym
Study on effects of banana intake and intake time on blood glucose levels and spike.
Scientific Title
Study on effects of banana intake and intake time on blood glucose levels and spike.
Scientific Title:Acronym
Study on effects of banana intake and intake time on blood glucose levels and spike.
Region
| Japan |
Condition
Condition
Healthy Adults
Classification by specialty
| Not applicable |
Classification by malignancy
Others
Genomic information
NO
Objectives
Narrative objectives1
Investigate the effects of continuous banana intake (about 120 g of edible portion) every day for two weeks on blood glucose levels measured by a continuous glucose meter, body composition, blood glucose metabolism, and biochemical parameters in a randomized parallel group comparative study for three groups: breakfast first group, dinner last group, and no intake group.
Basic objectives2
Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase
Assessment
Primary outcomes
Postprandial blood glucose (measured by a continuous blood glucose meter)
Key secondary outcomes
Fasting blood index (total protein, albumin, total cholesterol, LDL cholesterol, HDL cholesterol, neutral fat, urea nitrogen, creatinine, uric acid, aspartate aminotransferase(AST), alanine aminotransferase(ALT), HbA1C, glucose, glycoalbumin, 1.5AG, insulin, sodium, potassium, chlorine, calcium, magnesium, inorganic phosphorus, serum iron, blood count, ferritin)
Body composition (body weight, BMI, lean body mass)
Base
Study type
Interventional
Study design
Basic design
Parallel
Randomization
Randomized
Randomization unit
Individual
Blinding
Single blind -investigator(s) and assessor(s) are blinded
Control
No treatment
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
3
Purpose of intervention
Prevention
Type of intervention
| Food |
Interventions/Control_1
Ingest approximately 120 g of bananas edible portion at the beginning of breakfast every day for 2 weeks.
Interventions/Control_2
Ingest approximately 120 g of bananas edible portion at the end of dinner every day for 2 weeks.
Interventions/Control_3
Do not ingest bananas for 2 weeks.
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 40 | years-old | <= |
Age-upper limit
| 60 | years-old | > |
Gender
Male and Female
Key inclusion criteria
1.Persons who received a sufficient explanation of the purpose and contents of the exam, have the capacity to consent, applied with free will with sufficient understanding, and agreed to participate with a written document
2.Healthy Japanese who are 40 years old or more and under 60 years old at the time of obtaining consent
3.Persons who can wear a continuous blood glucose meter on their arm at home
Key exclusion criteria
1.Persons who are currently suffering from some kind of disease and are judged by the investigator to need treatment
2.Persons with severe anemia
3.Pregnant, lactating, pregnant
4.Persons who may cause allergic symptoms to the ingredients contained in the test food
5.Persons with alcoholism or other mental disorders
6.Persons who have a smoking habit, those who have quit smoking for less than 10 years
7.Persons with borderline diabetes or already diagnosed diabetes, fasting blood glucose of 110 mg/dl or higher, or HbA1c of 6.5% or higher, or blood glucose of 140 mg/dl or higher in 2 hours of 75g oral glucose tolerance test
8.Persons who may change their lifestyle during the examination period (night shift, long trip, etc.)
9.Persons who may develop seasonal allergic symptoms such as pollinosis during the test period
10.Persons who plan to take new health foods and supplement foods during the examination period
11.Persons who have received hormone replacement therapy within the past 6 months
12.Persons who have been treated with hospitalization within the past 6 months
13.Persons who are scheduled for imaging tests such as X-ray, MRI, CT scan, etc. during the continuous blood glucose monitoring period.
14.Persons who participate in other clinical studies or participated in the last 3 months or plan to participate in other clinical studies.
15.Persons who have had risk in the past or are at risk for contact dermatitis.
16.Persons who are judged by the investigator to be inappropriate for this study.
Target sample size
54
Research contact person
Name of lead principal investigator
| 1st name | Mitsuko |
| Middle name | |
| Last name | Ito |
Organization
Akasaka Family Clinic
Division name
Clinic Director
Zip code
107-0052
Address
Akasaka Plaza Building 3F, 2-15-15 Akasaka, Minato-ku, Tokyo, JAPAN
TEL
03-5562-8825
info@afc.tokyo
Public contact
Name of contact person
| 1st name | Takamasa |
| Middle name | |
| Last name | Masuda |
Organization
Healthcare Systems Co., Ltd.
Division name
Clinical Research Department
Zip code
105-0004
Address
Nisshin Tatemono Shinbashi Bld. 7F, 4-6-15 Shinbashi, Minato-ku, Tokyo, JAPAN
TEL
03-6809-2722
Homepage URL
masudat@hc-sys.jp
Sponsor or person
Institute
Akasaka Family Clinic
Institute
Department
Personal name
Funding Source
Organization
Japan Banana Importers Association.
Organization
Division
Category of Funding Organization
Profit organization
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
The Ethics Committee of Healthcare Systems Co., Ltd
Address
Nisshin Tatemono Shinbashi Bld. 7F, 4-6-15 Shinbashi, Minato-ku, Tokyo, JAPAN
Tel
03-6809-2722
soumu@hc-sys.jp
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
Other administrative information
Date of disclosure of the study information
| 2023 | Year | 01 | Month | 13 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
50
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2022 | Year | 12 | Month | 20 | Day |
Date of IRB
| 2022 | Year | 12 | Month | 20 | Day |
Anticipated trial start date
| 2023 | Year | 01 | Month | 16 | Day |
Last follow-up date
| 2023 | Year | 02 | Month | 28 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
Management information
Registered date
| 2023 | Year | 01 | Month | 13 | Day |
Last modified on
| 2023 | Year | 07 | Month | 14 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000056991
